Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 1, 2010, Pages 43-52

  Gabizon, Alberto ^a,b   Tzemach, Dina ^a   Gorin, Jenny ^a   Mak, Lidia ^a   Amitay, Yasmine ^a,b   Shmeeda, Hilary ^a   Zalipsky, Samuel ^c,d  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c ALZA CORPORATION   (United States)

^d Intradigm Corporation   (United States)

Author keywords

Cancer therapy; Doxorubicin; Folate receptor; Liposome; Targeting; Tumor model

Indexed keywords

DISTEAROYLPHOSPHATIDYLETHANOLAMINE; DOXORUBICIN; FOLATE RECEPTOR; FOLIC ACID; LIPOSOME; MACROGOL; PHOSPHOLIPID; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; CARRIER PROTEIN; CELL SURFACE RECEPTOR; DRUG DERIVATIVE; FOLATE BINDING PROTEIN; FOLATE-BINDING PROTEIN; MACROGOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES TUMOR; BINDING KINETICS; CANCER CELL CULTURE; CONTROLLED STUDY; DEATH; DRUG CONJUGATION; DRUG FORMULATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CELL SURVIVAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SCREENING; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; NEOPLASM; NUDE MOUSE; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARRIER PROTEINS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; FOLIC ACID; HUMANS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; POLYETHYLENE GLYCOLS; RECEPTORS, CELL SURFACE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77951890850     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1132-4     Document Type: Article

References (43)

1. Solomon R, Gabizon AA (2008) Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal doxorubicin. Clin Lymphoma Myeloma 8:21-32
2. Ewer MS, Martin FJ, Henderson C, Shapiro CL, Benjamin RS, Gabizon AA (2004) Cardiac safety of liposomal anthracyclines. Semin Oncol 31:161-181
3. Woodle MC, Lasic DD (1992) Sterically stabilized liposomes. Biochim Biophys Acta 1113:171-199
4. Gabizon A, Papahadjopoulos D (1988) Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 85:6949-6953
5. Lukyanov AN, Elbayoumi TA, Chakilam AR, Torchilin VP (2004) Tumor-targeted liposomes: doxorubicin-loaded longcirculating liposomes modified with anti-cancer antibody. J Control Release 100:135-144
6. Pastorino F, Brignole C, Marimpietri D et al (2003) Doxorubicinloaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res 63:86-92
7. Park JW, Kirpotin DB, Hong K et al (2001) Tumor targeting using anti-her2 immunoliposomes. J Control Release 74:95-113
8. Mamot C, Drummond DC, Greiser U et al (2003) Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR-and EGFRvIII-overexpressing tumor cells. Cancer Res 63:3154-3161
9. Kobayashi T, Ishida T, Okada Y, Ise S, Harashima H, Kiwada H (2007) Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Int J Pharm 32 9:94-102
10. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP (2005) Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 338:284-293
11. Lee RJ, Low PS (1994) Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem 269:3198-3204
12. Wang S, Low PS (1998) Folate-mediated targeting of antineoplastic drugs, imaging agents, and nucleic acids to cancer cells. J Control Release 53:39-48
13. Leamon CP (2008) Folate-targeted drug strategies for the treatment of cancer. Curr Opin Investig Drugs 9:1277-1286
14. Yang J, Chen H, Vlahov IR, Cheng JX, Low PS (2006) Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging. Proc Natl Acad Sci USA 103:13872-13877
15. Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S (2004) Tumor cell targeting of liposome-entrapped drugs with phospholipidanchored folic acid-PEG conjugates. Adv Drug Deliv Rev 56:1177-1192
16. Leamon CP, Cooper SR, Hardee GE (2003) Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo. Bioconjug Chem 14:738-747
17. Gabizon A, Horowitz AT, Goren D, Tzemach D, Shmeeda H, Zalipsky S (2003) In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin Cancer Res 9:6551-6559
18. Kirpotin DB, Drummond DC, Shao Y et al (2006) Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 66:6732-6740
19. Allen TM, Sapra P, Moase E (2002) Use of the post-insertion method for the formation of ligand-coupled liposomes. Cell Mol Biol Lett 7:217-219
20. Uster PS, Allen TM, Daniel BE, Mendez CJ, Newman MS, Zhu GZ (1996) Insertion of poly (ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time. FEBS Lett 386:243-246
21. Zalipsky S, Mullah N, Harding JA, Gittelman J, Guo L, DeFrees SA (1997) Poly (ethylene glycol)-grafted liposomes with oligopeptide or oligosaccharide ligands appended to the termini of the polymer chains. Bioconjug Chem 8:111-118
22. Shmeeda H, Mak L, Tzemach D, Astrahan P, Tarshish M, Gabizon A (2006) Intracellular uptake and intracavitary targeting of folateconjugated liposomes in a mouse lymphoma model with up-regulated folate receptors. Mol Cancer Ther 5:818-824
23. Gabizon A, Horowitz AT, Goren D et al (1999) Targeting folate receptor with folate linked to extremities of poly (ethylene glycol)-grafted liposomes: in vitro studies. Bioconjug Chem 10:289-298
24. Cabanes A, Tzemach D, Goren D, Horowitz AT, Gabizon A (1998) Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model. Clin Cancer Res 4:499-505
25. Shen DW, Cardarelli C, Hwang J et al (1986) Multiple drugresistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J Biol Chem 261:7762-7770
26. Gabizon AA, Tzemach D, Horowitz AT, Shmeeda H, Yeh J, Zalipsky S (2006) Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes. Clin Cancer Res 12:1913-1920
27. Gabizon A, Shmeeda H, Barenholz Y (2003) Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 42:419-436
28. Gabizon AA, Shmeeda H, Zalipsky S (2006) Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res 16:175-183
29. Huang SK, Lee KD, Hong K, Friend DS, Papahadjopoulos D (1992) Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res 52:5135-5143
30. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK (1994) Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 54:3352-3356
31. Pan XQ, Wang H, Lee RJ (2003) Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model. Pharm Res 20:417-422
32. Saul JM, Annapragada A, Natarajan JV, Bellamkonda RV (2003) Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J Control Release 92:49-67
33. Zalipsky S, Mullah N, Qazen M (2004) Preparation of poly (ethylene glycol)-grafted liposomes with ligands at the extremities of polymer chains. Methods Enzymol 387:50-69
34. Shmeeda H, Tzemach D, Mak L, Gabizon A (2009) Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage. J Control Release 136:155-160
35. Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A (2000) Nuclear delivery of doxorubicin via folatetargeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res 6:1949-1957
36. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A (2006) Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 98:335-344
37. Lee RJ, Low PS (1995) Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta 1233:134-144
38. Matthay KK, Heath TD, Papahadjopoulos D (1984) Specific enhancement of drug delivery to AKR lymphoma by antibodytargeted small unilamellar vesicles. Cancer Res 44:1880-1886
39. Heath TD, Lopez NG, Stern WH, Papahadjopoulos D (1985) 5-Fluoroorotate: a new liposome-dependent cytotoxic agent. FEBS Lett 187:73-75
40. Kim JS, Heath TD (2000) In vitro cytotoxic effect of N-(phosphonacetyl)- L-aspartic acid in liposome against C-26 murine colon carcinoma. Arch Pharm Res 23:167-171
41. Gabizon A, Shmeeda H, Amitay Y et al (2009) Intracellular delivery of zoledronic acid by folate-targeted liposomes results in potent tumor cell cytotoxicity. Ann Oncol 20: iii32
42. Reddy JA, Abburi C, Hofland H et al (2002) Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors. Gene Ther 9:1542-1550
43. Chiu SJ, Marcucci G, Lee RJ (2006) Efficient delivery of an antisense oligodeoxyribonucleotide formulated in folate receptortargeted liposomes. Anticancer Res 26:1049-1056